HT
BBIO icon

HAP Trading’s BridgeBio Pharma BBIO Stock Holding History

HAP Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,500
Closed -$15.6K – 689
2024
Q2 		$15.6K Sell
62,500
-50,000
-44% -$1.37M ﹤0.01% 547
2024
Q1 		$68.4K Buy
+112,500
New +$3.83M 0.01% 391
2023
Q3 		– Sell
-437,200
Closed -$644K – 1045
2023
Q2 		$644K Buy
+437,200
New +$6.58M 0.11% 164
2022
Q3 		– Sell
-14,200
Closed -$17K – 1736
2022
Q2 		$17K Sell
14,200
-29,500
-68% -$247K ﹤0.01% 1364
2022
Q1 		$45K Sell
43,700
-446,900
-91% -$4.59M ﹤0.01% 1295
2021
Q4 		$43K Buy
490,600
+480,600
+4,806% +$20.3M ﹤0.01% 1540
2021
Q3 		$22K Hold
10,000
– – ﹤0.01% 1769
2021
Q2 		$104K Buy
+10,000
New +$571K ﹤0.01% 1208
2020
Q3 		– Sell
-132,100
Closed -$294K – 1580
2020
Q2 		$294K Buy
132,100
+31,800
+32% +$969K 0.02% 578
2020
Q1 		$359K Buy
+100,300
New +$3.11M 0.02% 406

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's BBIO Position: Q2 2024 in Review

HAP Trading sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 38,039 shares — an estimated $1.04M sold.

HAP Trading first reported a position in BBIO in Q1 2021 and held it in 6 quarters. The position peaked at $7.56M in Q4 2021. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • HAP Trading reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • HAP Trading sold 38,039 BridgeBio Pharma shares in Q2 2024, an estimated $1.04M.
  • HAP Trading first reported a position in BridgeBio Pharma in Q1 2021 and held it in 6 quarters.
  • HAP Trading's BridgeBio Pharma position peaked at $7.56M in Q4 2021.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.